Literature DB >> 7254775

The natural history of gyrate atrophy of the choroid and retina.

K K Takki, R C Milton.   

Abstract

Twenty-nine Finnish patients (8-80 years old during follow-up) with hyperornithinemia and gyrate atrophy (HOGA) were followed 2 to 31 years to determine when and how rapidly visual acuities and visual functions were affected by the disease. Considerable variability was observed both in the age at which visual acuities began to decrease and the age at which visual acuities reached 20/200. Acuities in phakic eyes tended to decrease from 20/30 to 20/200 in ten years or less, while aphakic eyes exhibited generally slower loss of vision. Without benefit of cataract surgery, the percentage of eyes with acuity 20/200 or worse would have been 37% at age 30 and 64% at age 40, but through surgery actually performed was 20% at age 40. Constriction of visual fields with age was marked and correlated well with diminution in dark adaptation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7254775     DOI: 10.1016/s0161-6420(81)35031-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  24 in total

1.  Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroid and retina.

Authors:  T Wang; G Steel; A H Milam; D Valle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Progression of gyrate atrophy measured with ultra-wide-field imaging.

Authors:  Guillermo Salcedo-Villanueva; Miguel Paciuc-Beja; Cristina Villanueva-Mendoza; Mariana Harasawa; Jesse M Smith; Raul Velez-Montoya; Jeffrey L Olson; Scott C Oliver; Naresh Mandava; Hugo Quiroz-Mercado
Journal:  Int Ophthalmol       Date:  2015-05-26       Impact factor: 2.031

3.  The Proline/Citrulline Ratio as a Biomarker for OAT Deficiency in Early Infancy.

Authors:  Monique G M de Sain-van der Velden; Piero Rinaldo; Bert Elvers; Mick Henderson; John H Walter; Berthil H C M T Prinsen; Nanda M Verhoeven-Duif; Tom J de Koning; Peter van Hasselt
Journal:  JIMD Rep       Date:  2012-02-24

4.  OAT mutations and clinical features in two Japanese brothers with gyrate atrophy of the choroid and retina.

Authors:  Satoshi Katagiri; Tamaki Gekka; Takaaki Hayashi; Hiroyuki Ida; Toya Ohashi; Yoshikatsu Eto; Hiroshi Tsuneoka
Journal:  Doc Ophthalmol       Date:  2014-01-16       Impact factor: 2.379

5.  Ornithine-δ-Aminotransferase Inhibits Neurogenesis During Xenopus Embryonic Development.

Authors:  Ying Peng; Sandra K Cooper; Yi Li; Jay M Mei; Shuwei Qiu; Gregory L Borchert; Steven P Donald; Hsiang-Fu Kung; James M Phang
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

6.  Gyrate atrophy of the choroid and retina: 15 Japanese patients.

Authors:  S Hayasaka; T Shiono; K Mizuno; C Sasayama; S Akiya; Y Tanaka; M Hayakawa; Y Miyake; N Ohba
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

7.  Gyrate atrophy of the choroid and retina: assignment of the ornithine aminotransferase structural gene to human chromosome 10 and mouse chromosome 7.

Authors:  J J O'Donnell; K Vannas-Sulonen; T B Shows; D R Cox
Journal:  Am J Hum Genet       Date:  1988-12       Impact factor: 11.025

8.  Gyrate atrophy of choroid and retina with myopia, cataract and systemic proximal myopathy: A rare case report from rural India.

Authors:  Surekha Bangal; Akshay Bhandari; Priyanka Dhaytadak; Pratik Gogri
Journal:  Australas Med J       Date:  2012-12-31

9.  Multimodal characterization of a novel mutation causing vitamin B6-responsive gyrate atrophy.

Authors:  Xuan Cui; Ruben Jauregui; Karen Sophia Park; Stephen H Tsang
Journal:  Ophthalmic Genet       Date:  2018-05-14       Impact factor: 1.803

10.  Bilateral choroidal neovascularization associated with gyrate atrophy managed with intravitreal bevacizumab.

Authors:  Merve Inanc; Kemal Tekin; Mehmet Yasin Teke
Journal:  Int Ophthalmol       Date:  2017-05-30       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.